JPWO2019165097A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019165097A5 JPWO2019165097A5 JP2020544206A JP2020544206A JPWO2019165097A5 JP WO2019165097 A5 JPWO2019165097 A5 JP WO2019165097A5 JP 2020544206 A JP2020544206 A JP 2020544206A JP 2020544206 A JP2020544206 A JP 2020544206A JP WO2019165097 A5 JPWO2019165097 A5 JP WO2019165097A5
- Authority
- JP
- Japan
- Prior art keywords
- uapc
- cell
- cells
- immune cells
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 11
- 210000002865 immune cell Anatomy 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 210000004700 fetal blood Anatomy 0.000 claims 5
- 210000000822 natural killer cell Anatomy 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100036008 CD48 antigen Human genes 0.000 claims 1
- 108010084313 CD58 Antigens Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 claims 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100030704 Interleukin-21 Human genes 0.000 claims 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024062460A JP2024086827A (ja) | 2018-02-21 | 2024-04-09 | ユニバーサル抗原提示細胞およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633587P | 2018-02-21 | 2018-02-21 | |
| US62/633,587 | 2018-02-21 | ||
| PCT/US2019/018989 WO2019165097A1 (en) | 2018-02-21 | 2019-02-21 | Universal antigen presenting cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062460A Division JP2024086827A (ja) | 2018-02-21 | 2024-04-09 | ユニバーサル抗原提示細胞およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513860A JP2021513860A (ja) | 2021-06-03 |
| JPWO2019165097A5 true JPWO2019165097A5 (enrdf_load_stackoverflow) | 2022-03-01 |
| JP7591405B2 JP7591405B2 (ja) | 2024-11-28 |
Family
ID=67686940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544206A Active JP7591405B2 (ja) | 2018-02-21 | 2019-02-21 | ユニバーサル抗原提示細胞およびその使用 |
| JP2024062460A Pending JP2024086827A (ja) | 2018-02-21 | 2024-04-09 | ユニバーサル抗原提示細胞およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062460A Pending JP2024086827A (ja) | 2018-02-21 | 2024-04-09 | ユニバーサル抗原提示細胞およびその使用 |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178701A1 (en) * | 2020-03-05 | 2021-09-10 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| CA3089853A1 (en) | 2018-02-01 | 2019-08-08 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| MX2021011816A (es) * | 2019-03-29 | 2021-10-22 | Univ Texas | Metodos para produccion de celulas car-nk y uso de las mismas. |
| WO2022242710A1 (zh) * | 2021-05-19 | 2022-11-24 | 上海诗健生物科技有限公司 | 一种特异性识别baff-r的嵌合抗原受体分子及其应用 |
| CN113832190A (zh) * | 2021-09-24 | 2021-12-24 | 中海峡(福建)细胞生物科技有限公司 | 一种利用基因工程修饰的滋养细胞的制备方法及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5750356A (en) | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
| US5939281A (en) | 1996-09-16 | 1999-08-17 | Case Western Reserve University | Detecting alloreactivity |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6969609B1 (en) * | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| EP1100807A1 (en) | 1998-07-27 | 2001-05-23 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| EP1673389A2 (en) | 2003-10-10 | 2006-06-28 | Xencor Inc. | Novel variants of cd40l protein |
| JP5070045B2 (ja) * | 2004-05-27 | 2012-11-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 新規人工抗原提示細胞およびそれらの用途 |
| PT1879599E (pt) | 2005-04-20 | 2014-01-23 | Hutchinson Fred Cancer Res | Métodos, composições e artigos de fabrico para aumentar a capacidade de sobrevivência de células, tecidos, órgãos, e organismos |
| US9121008B2 (en) * | 2005-08-31 | 2015-09-01 | University Of Utah Research Foundation | Development of natural killer cells and functional natural killer cell lines |
| WO2009039854A2 (en) * | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| US9062287B2 (en) * | 2009-09-11 | 2015-06-23 | Takara Bio Inc. | Process for production of natural killer cells |
| WO2013163171A1 (en) | 2012-04-24 | 2013-10-31 | Kaufman Dan S | Method for developing natural killer cells from stem cells |
| LT3578201T (lt) * | 2012-06-28 | 2023-05-25 | University Of Central Florida Research Foundation Incorporated | Nk ląstelių metodai ir kompozicijos |
| JP6775426B2 (ja) * | 2014-03-07 | 2020-10-28 | エメルセル エスエーエス | 臍帯血由来のプールｎｋ細胞並びにがん及び慢性感染症の治療のためのこれらの用途 |
| WO2015154012A1 (en) * | 2014-04-03 | 2015-10-08 | Memorial Sloan-Kettering Cancer Center | Clonogenic natural killer (nk) cell populations and methods of producing and using such populations |
| US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
| JP7049830B2 (ja) | 2014-10-27 | 2022-04-07 | ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド | ナチュラルキラー細胞のための方法及び組成物 |
| CA2965521A1 (en) * | 2014-10-31 | 2016-05-06 | Baylor College Of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| US11154572B2 (en) * | 2015-06-05 | 2021-10-26 | Board Of Regents, The University Of Texas System | Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type |
| EP3138905A1 (en) * | 2015-09-04 | 2017-03-08 | Miltenyi Biotec GmbH | Method for natural killer cell expansion |
| US11555177B2 (en) | 2016-07-13 | 2023-01-17 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
| EP3487991B1 (en) * | 2016-07-25 | 2022-09-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing modified natural killer cells and methods of use |
| WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
| EP4471129A3 (en) * | 2018-11-29 | 2025-02-19 | Board of Regents, The University of Texas System | Methods for ex vivo expansion of natural killer cells and use thereof |
-
2019
- 2019-02-21 CN CN201980021995.0A patent/CN112292137A/zh active Pending
- 2019-02-21 EP EP19757670.5A patent/EP3755347B1/en active Active
- 2019-02-21 PT PT197576705T patent/PT3755347T/pt unknown
- 2019-02-21 BR BR112020016876-9A patent/BR112020016876A2/pt unknown
- 2019-02-21 KR KR1020207027108A patent/KR20200123459A/ko not_active Ceased
- 2019-02-21 CA CA3091671A patent/CA3091671A1/en active Pending
- 2019-02-21 US US16/970,930 patent/US20200390815A1/en active Pending
- 2019-02-21 MX MX2020008801A patent/MX2020008801A/es unknown
- 2019-02-21 FI FIEP19757670.5T patent/FI3755347T3/fi active
- 2019-02-21 TW TW108105835A patent/TW202000214A/zh unknown
- 2019-02-21 WO PCT/US2019/018989 patent/WO2019165097A1/en active IP Right Grant
- 2019-02-21 DK DK19757670.5T patent/DK3755347T3/da active
- 2019-02-21 JP JP2020544206A patent/JP7591405B2/ja active Active
- 2019-02-21 AU AU2019226021A patent/AU2019226021A1/en active Pending
- 2019-02-21 SG SG11202008008UA patent/SG11202008008UA/en unknown
-
2024
- 2024-04-09 JP JP2024062460A patent/JP2024086827A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ye et al. | Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes | |
| Knorr et al. | Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy | |
| JPWO2019165121A5 (enrdf_load_stackoverflow) | ||
| Schmidt-Wolf et al. | Activated T cells and cytokine-induced CD3+ CD56+ killer cells | |
| Topalian et al. | Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials | |
| CA2848121C (en) | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment | |
| JP2014526244A5 (enrdf_load_stackoverflow) | ||
| Zappasodi et al. | The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells | |
| JP2024086827A5 (enrdf_load_stackoverflow) | ||
| Gervais et al. | Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency | |
| RU2011121630A (ru) | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний | |
| van Eck van der Sluijs et al. | Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses | |
| CN115282165A (zh) | 来自胎盘的自然杀伤细胞 | |
| JPWO2019165097A5 (enrdf_load_stackoverflow) | ||
| Berglund et al. | Isolation, expansion and functional assessment of CD4+ CD25+ FoxP3+ regulatory T cells and Tr1 cells from uremic patients awaiting kidney transplantation | |
| Liu et al. | Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma | |
| Devetten et al. | Hematopoietic cell transplantation: progress and obstacles | |
| Okas et al. | Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation | |
| Pandolfino et al. | High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement | |
| Bregni et al. | The second international meeting on allogeneic transplantation in solid tumors | |
| JPWO2020112493A5 (enrdf_load_stackoverflow) | ||
| Kausche et al. | Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells | |
| SLINGLUFF JR et al. | Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes: implications of a renewable source of precursors for adoptive cellular immunotherapy | |
| EP0460065B1 (en) | A process for the generation of proliferating cd4 lymphocytes | |
| Cardenas et al. | The role of pDC, recipient Treg, and donor Treg in HSC engraftment: mechanisms of facilitation |